passages: 3405
passages: document
passages: Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder . A double-blind controlled study comparing the effects of bupropion to doxepin in outpatients with primary depression was conducted to evaluate efficacy and safety differences between the two drugs . Following a 7-day placebo washout period , patients could be treated for up to 13 weeks on either treatment . Antidepressant response was assessed by the Hamilton Depression and Anxiety Scales , Clinical Global Severity and Improvement Ratings , and the Zung Self-Rating Depression Scale . Comparable efficacy between the compounds was found across the 13-week study . Doxepin differed from bupropion mainly on the sleep factor of the Hamilton Depression Scale , with doxepin improving sleep to a greater extent than bupropion . Doxepin produced a greater incidence of anticholinergic side effects , including dry mouth , constipation , sleepiness , and tiredness , in comparison to bupropion . Also , increased appetite and weight gain were consistent side effects of doxepin relative to bupropion .
entities: 3406
entities: Intervention_Pharmacological
entities: doxepin
entities: 3407
entities: Intervention_Pharmacological
entities: bupropion
entities: 3408
entities: Intervention_Pharmacological
entities: bupropion
entities: 3409
entities: Intervention_Pharmacological
entities: doxepin
entities: 3410
entities: Intervention_Control
entities: placebo
entities: 3411
entities: Intervention_Pharmacological
entities: Doxepin
entities: 3412
entities: Intervention_Pharmacological
entities: bupropion
entities: 3413
entities: Intervention_Pharmacological
entities: doxepin
entities: 3414
entities: Intervention_Pharmacological
entities: bupropion . Doxepin
entities: 3415
entities: Intervention_Pharmacological
entities: bupropion .
entities: 3416
entities: Intervention_Pharmacological
entities: doxepin
entities: 3417
entities: Intervention_Pharmacological
entities: bupropion .
entities: 3418
entities: Outcome_Other
entities: efficacy
entities: 3419
entities: Outcome_Other
entities: safety
entities: 3420
entities: Outcome_Mental
entities: Antidepressant response
entities: 3421
entities: Outcome_Mental
entities: Hamilton Depression and Anxiety Scales
entities: 3422
entities: Outcome_Mental
entities: Clinical Global Severity and Improvement Ratings
entities: 3423
entities: Outcome_Mental
entities: Zung Self-Rating Depression Scale
entities: 3424
entities: Outcome_Other
entities: efficacy
entities: 3425
entities: Outcome_Physical
entities: sleep
entities: 3426
entities: Outcome_Mental
entities: Hamilton Depression Scale
entities: 3427
entities: Outcome_Physical
entities: sleep
entities: 3428
entities: Outcome_Adverse-effects
entities: anticholinergic side effects
entities: 3429
entities: Outcome_Adverse-effects
entities: dry mouth , constipation , sleepiness , and tiredness
entities: 3430
entities: Outcome_Adverse-effects
entities: appetite and weight gain
entities: 3431
entities: Participant_Condition
entities: outpatients with a major depressive disorder .
entities: 3432
entities: Participant_Condition
entities: outpatients with primary depression